Cytokine Signalling Forum

Publications





December 15

Romatoid artritli hastalarda tocilizumab ya da adalimumab ile tedaviden sonra lipid ve lipid ile ilişkili kardovasküler risk belirteçlerindeki değişimin karşılaştırılması

Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N.
Ann Rheum Dis. 2015;0:1-7. doi:10.1136/annrheumdis-2015-207872 [Epub ahead of print]

RA patients have increased risk of CVD compared with the general population that is not fully explained by traditional risk factors. This is a post-hoc analysis of data from a clinical trial that compared IL-6 and TNF-α signaling inhibition to compare changes in lipids and lipid-associated CV risk markers in 324 patients treated with TCZ IV q4w or ADA SC q2w for 24 weeks. HDL-SAA and sPLA2 IIA is also measured in an additional subpopulation of 87 and 97 TCZ and ADA patients, respectively. ...

Keywords: IL-6, Tocilizumab, Cardiovascular

Translated by: Şafak Mirioğlu

December 14

Tocilizumab tedavisi sırasında oluşan majör kardiyovasküler advers olaylar için risk faktörlerinin değerlendirilmesi

Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS.
Arthritis Rheumatol. 2015;67(2):372–380

The risk of cardiovascular (CV) disease among RA patients, compared with the general population is well documented. Alongside this, studies have been able to establish that risk factors in RA patients are not wholly associated with traditional CV risk factors such as such as diabetes mellitus, hypertension, smoking, and dyslipidemia, suggesting a relationship between parameters of RA disease activity and increased CV risk. Additionally, IL-6 has been linked with the development of coronary heart...

Keywords: IL-6, Tocilizumab, Cardiovascular

Translated by: Ege Sinan TORUN